Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the fourth quarter, Holdings Channel reports. The firm owned 52,049 shares of the biopharmaceutical company’s stock after purchasing an additional 3,313 shares during the quarter. Erste Asset Management GmbH’s holdings in Regeneron Pharmaceuticals were worth $40,471,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $1,012,296,000. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the period. AQR Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after acquiring an additional 606,612 shares during the period. Invesco Ltd. boosted its stake in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares during the period. Finally, Caisse de depot et placement du Quebec boosted its stake in Regeneron Pharmaceuticals by 115.4% in the third quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock valued at $260,051,000 after acquiring an additional 247,780 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on REGN shares. Leerink Partners restated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Royal Bank Of Canada decreased their target price on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research note on Monday, May 18th. Wells Fargo & Company decreased their target price on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Regeneron Pharmaceuticals Stock Performance

REGN opened at $635.45 on Monday. The business’s 50 day moving average is $706.93 and its 200-day moving average is $742.43. The stock has a market cap of $67.18 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $485.00 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.22 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.